Trials / Active Not Recruiting
Active Not RecruitingNCT05995405
Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH
Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): a Prospective, Randomized Trial
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Grace Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to deliver nimodipine via IV directly into the bloodstream and to determine if this is as safe and tolerable as oral nimodipine capsules.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GTX-104 | Nimodipine IV infusion |
| DRUG | Nimotop 30 MG Oral Capsule | Oral nimodipine capsules |
Timeline
- Start date
- 2023-10-20
- Primary completion
- 2024-12-01
- Completion
- 2024-12-01
- First posted
- 2023-08-16
- Last updated
- 2024-10-01
Locations
22 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05995405. Inclusion in this directory is not an endorsement.